Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adi Vaknin

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
Pharmacological Research|August 12, 2019
MicroRNA signature associated with treatment response in myasthenia gravis: A further step towards precision medicinePaola Cavalcante, Tehila Mizrachi, Claudia Barzago, et al.
Journal of Neurology|July 12, 2023
Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group‏ ViewpointPanayiota Petrou, Anat Achiron, Esther Ganelin Cohen, et al.
JAMA Neurology|January 12, 2016
Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical TrialsPanayiota Petrou, Yael Gothelf, Zohar Argov, et al.
Frontiers in Immunology|October 15, 2024
Cognitive impairments in autoimmune encephalitis: the role of autoimmune antibodies and oligoclonal bandsAyal Rozenberg, Shahar Shelly, Adi Vaknin-Dembinsky, et al.
Brain and Behavior|June 28, 2024
The effect of COVID-19 vaccination on multiple sclerosis activity as reflected by MRIEsther Ganelin-Cohen, Chen Buxbaum, Noam Bosak, et al.
Archives of Neurology|October 13, 2010
Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosisDimitrios Karussis, Clementine Karageorgiou, Adi Vaknin-Dembinsky, et al.
International Immunopharmacology|March 18, 2020
RIC3, the cholinergic anti-inflammatory pathway, and neuroinflammationYael Ben-David, Sara Kagan, Hagit Cohen Ben-Ami, et al.
Journal of the Neurological Sciences|December 7, 2021
Effect of natalizumab treatment on the rate of No Evidence of Disease Activity in young adults with multiple sclerosis in relation to pubertal stageShay Menascu, Aviva Fattal-Valevski, Adi Vaknin-Dembinsky, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 25, 2026
Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategiesLior Fuchs, Ifat Vigiser, Hadar Kolb, et al.
Plos One|December 29, 2012
T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trialDimitrios Karussis, Hagai Shor, Julia Yachnin, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Pharmacological Research|August 12, 2019
MicroRNA signature associated with treatment response in myasthenia gravis: A further step towards precision medicinePaola Cavalcante, Tehila Mizrachi, Claudia Barzago, et al.
Journal of Neurology|July 12, 2023
Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group‏ ViewpointPanayiota Petrou, Anat Achiron, Esther Ganelin Cohen, et al.
JAMA Neurology|January 12, 2016
Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical TrialsPanayiota Petrou, Yael Gothelf, Zohar Argov, et al.
Frontiers in Immunology|October 15, 2024
Cognitive impairments in autoimmune encephalitis: the role of autoimmune antibodies and oligoclonal bandsAyal Rozenberg, Shahar Shelly, Adi Vaknin-Dembinsky, et al.
Brain and Behavior|June 28, 2024
The effect of COVID-19 vaccination on multiple sclerosis activity as reflected by MRIEsther Ganelin-Cohen, Chen Buxbaum, Noam Bosak, et al.
Archives of Neurology|October 13, 2010
Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosisDimitrios Karussis, Clementine Karageorgiou, Adi Vaknin-Dembinsky, et al.
International Immunopharmacology|March 18, 2020
RIC3, the cholinergic anti-inflammatory pathway, and neuroinflammationYael Ben-David, Sara Kagan, Hagit Cohen Ben-Ami, et al.
Journal of the Neurological Sciences|December 7, 2021
Effect of natalizumab treatment on the rate of No Evidence of Disease Activity in young adults with multiple sclerosis in relation to pubertal stageShay Menascu, Aviva Fattal-Valevski, Adi Vaknin-Dembinsky, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 25, 2026
Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategiesLior Fuchs, Ifat Vigiser, Hadar Kolb, et al.
Plos One|December 29, 2012
T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trialDimitrios Karussis, Hagai Shor, Julia Yachnin, et al.
Pageof 9